BridgeMD
Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer (NeoCol)
EU CTIS ID: 2024-514294-22-01
What this study is testing
To investigate the effect of neoadjuvant chemotherapy in locally advanced colon cancer as estimated by disease free survival.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Histologically verified locally advanced T3 (ETI > 5 mm) or T4 colon cancer assessed by CT scan. • Age ≥ 18 years • PS 0-2. • Hematology ANC ≥1.5x109/l. Thrombocytes ≥ 100x109/l. • Biochemistry Bilirubinemia ≤ 3 x upper normal level. ALAT ≤ 5 x upper normal value • Consent to translational research • Fertile women must present a negative pregnancy test and use secure contraceptives during and 3 months after treatment. • Written and orally informed consent.
You likely can't join if
- • Patients with distant metastases. • Acute operation • Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before inclusion. • Active, serious infection or other serious disease. • Peripheral neuropathy NCI grade > 1 • Other malignant disease within 5 years prior to study enrollment, except basocellular or squamous skin cancer and carcinoma in situ cervicis uteri. • Other investigational treatment within 30 days prior to treatment start. • Hypersensitivity to one or more of the active or auxiliary substances.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.